Literature DB >> 15291975

Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia.

Clive S Zent1, Neil E Kay.   

Abstract

Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course and outcome. Recent advances in the diagnosis and molecular characterization of CLL permit improved prediction of disease prognosis, which could result in better management. We review the biology and diagnosis of CLL and the role of analysis of immunoglobulin heavy-chain variable region mutation status, molecular cytogenetics (interphase fluorescence in situ hybridization), and the expression of CD38 and ZAP-70 in the evaluation and management of patients with CLL.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15291975     DOI： 10.1007/s11912-004-0060-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  49 in total

1.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

Authors:  Terry J Hamblin; Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Peter W Thomas; Freda K Stevenson; David G Oscier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.

Authors:  D F Jelinek; R C Tschumper; S M Geyer; N D Bone; G W Dewald; C A Hanson; M J Stenson; T E Witzig; A Tefferi; N E Kay
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

3.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.

Authors:  S Ibrahim; M Keating; K A Do; S O'Brien; Y O Huh; I Jilani; S Lerner; H M Kantarjian; M Albitar
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

5.  Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.

Authors:  G Dighiero; K Maloum; B Desablens; B Cazin; M Navarro; R Leblay; M Leporrier; J Jaubert; G Lepeu; B Dreyfus; J L Binet; P Travade
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

Review 6.  Impairments in immune cell function in B cell chronic lymphocytic leukemia.

Authors:  M M Bartik; D Welker; N E Kay
Journal:  Semin Oncol       Date:  1998-02       Impact factor: 4.929

7.  Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

Authors:  Gerard Tobin; Ulf Thunberg; Anna Johnson; Inger Eriksson; Ola Söderberg; Karin Karlsson; Mats Merup; Gunnar Juliusson; Juhani Vilpo; Gunilla Enblad; Christer Sundström; Göran Roos; Richard Rosenquist
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

8.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Authors:  Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

9.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

10.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.